```json
{
"content": [
{
"type": "paragraph",
"content": "The past 18 months have reshaped the Saline Laxatives industry trends as manufacturers race to meet demand for gentle, on-the-go relief. In March 2024, Bayer acquired a controlling stake in Nordic startup LaxaGo, gaining a patented micro-encapsulated magnesium oxide that releases only in the colonic pH, cutting cramping reports by 32 % in Phase III data. Meanwhile, Perrigo and Alcon formed a co-distribution pact (Q2 2024) to place saline laxative mini-sachets alongside eye-care aisles in 12,000 U.S. pharmacies, capitalizing on cross-category footfall."
},
{
"type": "paragraph",
content: "Regulatory momentum arrived when the FDA finalized the saline osmotic monograph (November 2023), capping sodium content at 1,175 mg per adult dose and pushing firms toward low-sodium and magnesium-citrate hybrids. Consumer surveys by IQVIA (Q1 2025) show 41 % of Gen-Z buyers prefer travel-friendly stick-packs over bottles, prompting Sun Pharma to launch EZ-Go Saline in January 2025 with QR-code hydration reminders. Finally, venture funding hit a record $88 M in 2024, led by Sequoia’s $22 M bet on BioLax Labs, whose AI-driven salt-gradient capsule is slated for 2026 OTC debut."
}
]
}
```
